| P/E (FY) | 16.9 | Sales (TTM) | $514.7M |
| Earnings (TTM) | $2.7M | ROE | 13.15% |
| Net Margin | 6.56% | ROIC | 21.11% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 7.72% | Sales Growth 3Y | 7.76% |
Organogenesis Holdings is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and the surgical and sports medicine markets in the United States. Its advanced wound care products include placental allografts such as Affinity and Novachor, the bioengineered skin substitute Apligraf, the dermal substitute Dermagraft, NuShield, and the PuraPly antimicrobial barriers.
| Market Cap | $325.5M | Trading Days | 2389 |
| 52W High | 7.08 |
| 52W Low | 2.04 |
| % Off High | −64.25% |
| YTD | −51.16% | 1Y | −49.60% |
| 3Y | −40.75% | 5Y | −83.49% |
| Since incept. (ann.) | −13.16% |
Product 100% · Grant 0%
| Ann. Volatility (1Y) | 74.48% | Ann. Volatility (3Y) | 100.84% |
| Sharpe (1Y) | −0.60 | Sharpe (3Y) | 0.28 |
| Max Drawdown (1Y) | −65.75% | Max Drawdown (3Y) | −65.75% |
| Beta (3Y, vs SPY) | 1.90 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| CATX | Perspective Therapeutics, Inc. | $327.3M | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $328.9M | — |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
| VNDA | Vanda Pharmaceuticals Inc. | $310.3M | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.9M | — |
| ABEO | ABEONA THERAPEUTICS INC. | $343.1M | 6.0 |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| LYEL | Lyell Immunopharma, Inc. | $303.1M | — |
| FHTX | Foghorn Therapeutics Inc. | $301.2M | — |
| DMAC | DiaMedica Therapeutics Inc. |
| $357.8M |
| — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
